Antigen ID	TAR0FPXYP
Antigen Name	Undisclosed
Gene Name	Undisclosed

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Monoclonal antibody 45-2D9-haematoporphyrin conjugate	Hematoporphyrin	Undisclosed	Undisclosed	[1]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Monoclonal antibody SN7-ricin chain A conjugate	Deglycosylated ricin A-chain (dgA)	Undisclosed	Undisclosed	[2]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	VL-DAB31-SN38	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	Mal-Cyc-PEG3-DAB	[3]
ADC Info	ROS-responsive SN38 ADC	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	Mal-Cyc-PEG3-DAB	[3]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	CBX-12	Exatecan	DNA topoisomerase 1 (TOP1)	Undisclosed	[4]
ADC Info	IBI129	Undisclosed	Undisclosed	Undisclosed	[5]
ADC Info	CPO-204	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DAN-222	Undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	DB-1202	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	DXC-009	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC004A	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	MG1901	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	MG2001	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	MG2002A	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	TUB-030	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	SYS6010	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	DS001	Undisclosed	Undisclosed	Undisclosed	[13]
ADC Info	TORL-3-600	Undisclosed	Undisclosed	Undisclosed	[14]
ADC Info	SHR-4602	Undisclosed	Undisclosed	Undisclosed	[15]
ADC Info	TORL-4-500	Undisclosed	Undisclosed	Undisclosed	[16]
ADC Info	hu5B1-TCO	Undisclosed	Undisclosed	Undisclosed	[17]
ADC Info	RC-168	Undisclosed	Undisclosed	Undisclosed	[18]
ADC Info	RC-178	Undisclosed	Undisclosed	Undisclosed	[18]
ADC Info	RC-188	Undisclosed	Undisclosed	Undisclosed	[18]
ADC Info	XYD-9668-198	Undisclosed	Undisclosed	Undisclosed	[19]
ADC Info	XNW-28012	Undisclosed	Undisclosed	Undisclosed	[20]
ADC Info	DXC-006	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC1002	Undisclosed	Undisclosed	Undisclosed	[21]
ADC Info	PTM-001-ADC	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[22]
ADC Info	Bi-specific antibody drug conjugate	Undisclosed	Undisclosed	Undisclosed	[23]
ADC Info	AR081	Undisclosed	Undisclosed	Undisclosed	[24]
ADC Info	BC5084	Undisclosed	Undisclosed	Undisclosed	[25]
ADC Info	WTX-231	Undisclosed	Undisclosed	Undisclosed	[26]
ADC Info	WTX-222	Undisclosed	Undisclosed	Undisclosed	[26]
ADC Info	VIS-705	Undisclosed	Undisclosed	Undisclosed	[27]
ADC Info	VLS-201	Undisclosed	Undisclosed	Undisclosed	[28]
ADC Info	Anticancer antibody-drug conjugate (Vaccinex/Catalent Pharma Solutions)	Undisclosed	Undisclosed	Undisclosed	[29]
ADC Info	TUB-060	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	TUB-050	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	TUB-040	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	TAE-020	Undisclosed	Undisclosed	Undisclosed	[30]
ADC Info	TT-01	Undisclosed	Undisclosed	Undisclosed	[31]
ADC Info	SIM-005A	Undisclosed	Undisclosed	Undisclosed	[32]
ADC Info	SIM-002A	Undisclosed	Undisclosed	Undisclosed	[33]
ADC Info	SIB-004A	Undisclosed	Undisclosed	Undisclosed	[34]
ADC Info	BL-B029A1	Undisclosed	Undisclosed	Undisclosed	[35]
ADC Info	BL-M002A2	Undisclosed	Undisclosed	Undisclosed	[36]
ADC Info	SDV-1001	Undisclosed	Undisclosed	Undisclosed	[37]
ADC Info	ADC project 6 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[38]
ADC Info	ADC project 5 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[38]
ADC Info	ADC project 4 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[38]
ADC Info	BsAb-ADC (Medilink Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[39]
ADC Info	SOT106	Undisclosed	Undisclosed	Undisclosed	[40]
ADC Info	SMD-3117	Undisclosed	Undisclosed	Undisclosed	[41]
ADC Info	HY-0001	Undisclosed	Undisclosed	Undisclosed	[42]
ADC Info	BL-M005	Undisclosed	Undisclosed	Undisclosed	[43]
ADC Info	BL-M25D1	Undisclosed	Undisclosed	Undisclosed	[44]
ADC Info	BL-M22D1	Undisclosed	Undisclosed	Undisclosed	[44]
ADC Info	BL-M19D1	Undisclosed	Undisclosed	Undisclosed	[44]
ADC Info	BL-M15D1	Undisclosed	Undisclosed	Undisclosed	[44]
ADC Info	P-BsAb-ADC	Undisclosed	Undisclosed	Undisclosed	[45]
ADC Info	JY210	Undisclosed	Undisclosed	Undisclosed	[46]
ADC Info	JY208	Undisclosed	Undisclosed	Undisclosed	[46]
ADC Info	SY-1558	Undisclosed	Undisclosed	Undisclosed	[47]
ADC Info	MRX-23	Undisclosed	Undisclosed	Undisclosed	[48]
ADC Info	MG2106E	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	MG2011C	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	MG2002B	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	SGN-25	Undisclosed	Undisclosed	Undisclosed	[49]
ADC Info	JK-06	Undisclosed	Undisclosed	Undisclosed	[50]
ADC Info	RAD-501	Undisclosed	Undisclosed	Undisclosed	[51]
ADC Info	PLBA-001	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PSM-101	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	DN-028	Undisclosed	Undisclosed	Undisclosed	[54]
ADC Info	PHN-020	Undisclosed	Undisclosed	Undisclosed	[55]
ADC Info	PHN-010	Undisclosed	Undisclosed	Undisclosed	[55]
ADC Info	Antibody-drug conjugate containing OXS-2175 (Oxis Biotech/MultiCell ImmunoTherapeutics)	Undisclosed	Undisclosed	Undisclosed	[56]
ADC Info	OX-004	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	OBT542	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	OBT207	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	OBT029	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	Next generation antibody-drug conjugate (Oxford BioTherapeutics)	Undisclosed	Undisclosed	Undisclosed	[59]
ADC Info	NBT-578	Undisclosed	Undisclosed	Undisclosed	[60]
ADC Info	NBT-568	Undisclosed	Undisclosed	Undisclosed	[61]
ADC Info	NBT-528	Undisclosed	Undisclosed	Undisclosed	[62]
ADC Info	NTX-1107	Undisclosed	Undisclosed	Undisclosed	[63]
ADC Info	SO-N107	Undisclosed	Undisclosed	Undisclosed	[64]
ADC Info	NBE-003	Undisclosed	Undisclosed	Undisclosed	[65]
ADC Info	NBE-001	Undisclosed	Undisclosed	Undisclosed	[66]
ADC Info	AMT-676	Undisclosed	Undisclosed	Undisclosed	[67]
ADC Info	G-100 (Magenta Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[68]
ADC Info	MBK-101	Undisclosed	Undisclosed	Undisclosed	[69]
ADC Info	LCB-69	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-91	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB14-15nm	Undisclosed	Undisclosed	Undisclosed	[71]
ADC Info	LM-007	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	LM-006	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	LM-005	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	LM-004	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	LM-001	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	LM-317	Undisclosed	Undisclosed	Undisclosed	[73]
ADC Info	LM-008	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	KGX201	Undisclosed	Undisclosed	Undisclosed	[74]
ADC Info	IMB-213I	Undisclosed	Undisclosed	Undisclosed	[75]
ADC Info	IMB-212	Undisclosed	Undisclosed	Undisclosed	[75]
ADC Info	IKS-02	Undisclosed	Undisclosed	Undisclosed	[76]
ADC Info	IKS-04	Undisclosed	Undisclosed	Undisclosed	[76]
ADC Info	HDP-104	Undisclosed	Undisclosed	Undisclosed	[77]
ADC Info	DXC-020	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-019	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-018	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-017	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-016	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-015	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-014	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-013	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-012	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-011	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-010	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	DXC-004A	Undisclosed	Undisclosed	Undisclosed	[9]
ADC Info	Monoclonal Antibody-Drug Conjugate (Kind Pharmaceuticals)	Undisclosed	Undisclosed	Undisclosed	[78]
ADC Info	GMA-205	Undisclosed	Undisclosed	Undisclosed	[79]
ADC Info	SeeloMab-GEX	Undisclosed	Undisclosed	Undisclosed	[80]
ADC Info	P-1000	Undisclosed	Undisclosed	Undisclosed	[81]
ADC Info	GF-2014	Undisclosed	Undisclosed	Undisclosed	[82]
ADC Info	GR1018	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	GQ1011	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	EP-400	Undisclosed	Undisclosed	Undisclosed	[84]
ADC Info	PCG-N003	Undisclosed	Undisclosed	Undisclosed	[85]
ADC Info	PCG-C006	Undisclosed	Undisclosed	Undisclosed	[85]
ADC Info	PCG-C004	Undisclosed	Undisclosed	Undisclosed	[85]
ADC Info	PCG-C002	Undisclosed	Undisclosed	Undisclosed	[85]
ADC Info	DB-1312	Undisclosed	Undisclosed	Undisclosed	[86]
ADC Info	AccuADC-001	Undisclosed	Undisclosed	Undisclosed	[87]
ADC Info	CM-09	Undisclosed	Undisclosed	Undisclosed	[88]
ADC Info	CS-5002	Undisclosed	Undisclosed	Undisclosed	[89]
ADC Info	CBP-1609	Undisclosed	Undisclosed	Undisclosed	[90]
ADC Info	CAT-03-106	Undisclosed	Undisclosed	Undisclosed	[91]
ADC Info	BMT-125961	Undisclosed	Undisclosed	Undisclosed	[92]
ADC Info	BRKB-28	Undisclosed	Undisclosed	Undisclosed	[93]
ADC Info	BIO104	Undisclosed	Undisclosed	Undisclosed	[94]
ADC Info	BIO103	Undisclosed	Undisclosed	Undisclosed	[94]
ADC Info	BSC-4201	Undisclosed	Undisclosed	Undisclosed	[95]
ADC Info	BSC-4101	Undisclosed	Undisclosed	Undisclosed	[96]
ADC Info	BIO-201	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	BIO-108	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	BIO-107	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	BIO-110	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	BIO-109	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	JY-023	Undisclosed	Undisclosed	Undisclosed	[98]
ADC Info	AVP20	Undisclosed	Undisclosed	Undisclosed	[99]
ADC Info	Monoclonal Antibody-Drug Conjugate (Antengene)	Undisclosed	Undisclosed	Undisclosed	[100]
ADC Info	ANG-101	Undisclosed	Undisclosed	Undisclosed	[101]
ADC Info	AMB-015	Undisclosed	Undisclosed	Undisclosed	[102]
ADC Info	AbGn-108	Undisclosed	Undisclosed	Undisclosed	[103]
ADC Info	BIO-112	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	BL-M005A2	Dual-warhead	Undisclosed	Undisclosed	[104]
ADC Info	SMP-190	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Unique hydrophilic Linker	[105]
ADC Info	CBX-13	Mertansine DM4	Microtubule (MT)	Undisclosed	[106]
ADC Info	APH-0912	Docetaxel	Microtubule (MT)	Hydrophilic linker containing sugar molecules	[107]
ADC Info	TAK-ATACs	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[108]
ADC Info	Antibody targeted amanitin conjugate	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[109]
ADC Info	CBX-14	Multi-targetd DDR inhibitor	Epithelial discoidin domain-containing receptor 1 (DDR1)	Undisclosed	[106]
ADC Info	Spliceostatin-antibody-drug conjugate	Spliceostatin A	Splicing factor 3B subunit 1 (SF3B1)	Undisclosed	[110]
ADC Info	XMT-2175	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[111]
ADC Info	XMT-2068	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[111]
ADC Info	STING agonist ADC	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[112]
ADC Info	EX108	Undisclosed	Undisclosed	Undisclosed	[113]
ADC Info	ADRX-0706	Undisclosed	Undisclosed	Undisclosed	[114]
ADC Info	ADRX-0405	Undisclosed	Undisclosed	Undisclosed	[114]
ADC Info	SY-0833	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	SY-1211	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	SY-0625	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	AMB-101	Topoisomerase I inhibitor	DNA topoisomerase 1 (TOP1)	Undisclosed	[116]
ADC Info	BP-A102	Undisclosed	Undisclosed	Undisclosed	[117]
ADC Info	BP-A103	Undisclosed	Undisclosed	Undisclosed	[117]
ADC Info	3-NAntC	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	BR109	Undisclosed	Undisclosed	Undisclosed	[119]
ADC Info	NW-001	Undisclosed	Undisclosed	Undisclosed	[120]
ADC Info	FG-M131	Undisclosed	Undisclosed	Undisclosed	[121]
ADC Info	ADC001 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[122]
ADC Info	ZV03-ADC	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	WTX-116	Undisclosed	Undisclosed	Undisclosed	[26]
ADC Info	Second ADC (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[124]
ADC Info	LEAD ADC (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[125]
ADC Info	Additional antibody drug conjugate (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[126]
ADC Info	VLS-301	Undisclosed	Undisclosed	Undisclosed	[127]
ADC Info	Vas-202	Undisclosed	Undisclosed	Undisclosed	[128]
ADC Info	Vas-201	Undisclosed	Undisclosed	Undisclosed	[129]
ADC Info	TGM-005	Undisclosed	Undisclosed	Undisclosed	[130]
ADC Info	TGM-004	Undisclosed	Undisclosed	Undisclosed	[131]
ADC Info	TGM-003	Undisclosed	Undisclosed	Undisclosed	[132]
ADC Info	TGM-002	Undisclosed	Undisclosed	Undisclosed	[133]
ADC Info	Antibody boron conjugate radiopharmaceuticals (TAE Life Sciences)	Undisclosed	Undisclosed	Undisclosed	[134]
ADC Info	Antibody-drug conjugate 4 (Synthon)	Undisclosed	Undisclosed	Undisclosed	[135]
ADC Info	Antibody-drug conjugate 3 (Synthon)	Undisclosed	Undisclosed	Undisclosed	[136]
ADC Info	SAB-Y17	Undisclosed	Undisclosed	Undisclosed	[137]
ADC Info	SAB-Y1	Undisclosed	Undisclosed	Undisclosed	[137]
ADC Info	Antibody-drug conjugate (SynAffix)	Undisclosed	Undisclosed	Undisclosed	[138]
ADC Info	ADC project 7 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[38]
ADC Info	SMD-5033	Undisclosed	Undisclosed	Undisclosed	[139]
ADC Info	MRG-006	Undisclosed	Undisclosed	Undisclosed	[140]
ADC Info	MG2018	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	Antibody-drug conjugate (Sanofi/Seagen)	Undisclosed	Undisclosed	Undisclosed	[141]
ADC Info	APEC-3	Undisclosed	Undisclosed	Undisclosed	[142]
ADC Info	APEC-2	Undisclosed	Undisclosed	Undisclosed	[143]
ADC Info	PLBC-003	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBC-002	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBC-001	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBA-005	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBA-004	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBA-003	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	PLBA-002	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	DN-027	Undisclosed	Undisclosed	Undisclosed	[144]
ADC Info	Antibody-drug conjugate (Oxford BioTherapeutics/Boehringer Ingelheim)	Undisclosed	Undisclosed	Undisclosed	[145]
ADC Info	NBT-598	Undisclosed	Undisclosed	Undisclosed	[146]
ADC Info	NBT-588	Undisclosed	Undisclosed	Undisclosed	[147]
ADC Info	NBT-588	Undisclosed	Undisclosed	Undisclosed	[147]
ADC Info	NW-12-005	Undisclosed	Undisclosed	Undisclosed	[148]
ADC Info	MBC-301	Undisclosed	Undisclosed	Undisclosed	[149]
ADC Info	LCB-09A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-42A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-20A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-19A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-18A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-12A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-06A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-04A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-02A	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LCB-88	Undisclosed	Undisclosed	Undisclosed	[150]
ADC Info	LCB-85	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	LP-A18	Undisclosed	Undisclosed	Undisclosed	[151]
ADC Info	IOG-101	Undisclosed	Undisclosed	Undisclosed	[152]
ADC Info	DBAF-301	Undisclosed	Undisclosed	Undisclosed	[153]
ADC Info	IN30718	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	131I-ImmuRAIT-HCG	Undisclosed	Undisclosed	Undisclosed	[155]
ADC Info	Glaucoma therapy	Undisclosed	Undisclosed	Undisclosed	[156]
ADC Info	GBM-12401	Undisclosed	Undisclosed	Undisclosed	[157]
ADC Info	GMA-305	Undisclosed	Undisclosed	Undisclosed	[158]
ADC Info	GL-231	Undisclosed	Undisclosed	Undisclosed	[159]
ADC Info	GR-1016	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	GR-1015	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	GR-1014	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	GQ-1009	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	GQ-1010	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	M-131	Undisclosed	Undisclosed	Undisclosed	[160]
ADC Info	EVOLVE-104 ADC	Undisclosed	Undisclosed	Undisclosed	[161]
ADC Info	DOM-1314	Undisclosed	Undisclosed	Undisclosed	[162]
ADC Info	Antiviral Fc-conjugate (Cidara Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[163]
ADC Info	CRB-2107	Undisclosed	Undisclosed	Undisclosed	[164]
ADC Info	Monoclonal Antibody-Drug conjugate (Celltrion Chemical Research Institute/Immunogen/Celltrion)	Undisclosed	Undisclosed	Undisclosed	[165]
ADC Info	CT-P26	Undisclosed	Undisclosed	Undisclosed	[166]
ADC Info	LD016	Undisclosed	Undisclosed	Undisclosed	[167]
ADC Info	BSI-023	Undisclosed	Undisclosed	Undisclosed	[168]
ADC Info	BIOO-4	Undisclosed	Undisclosed	Undisclosed	[169]
ADC Info	BIOO-3	Undisclosed	Undisclosed	Undisclosed	[170]
ADC Info	BIOO-2	Undisclosed	Undisclosed	Undisclosed	[171]
ADC Info	BIOO-1	Undisclosed	Undisclosed	Undisclosed	[172]
ADC Info	Advanced antibody drug conjugate (Belrose Pharma)	Undisclosed	Undisclosed	Undisclosed	[173]
ADC Info	NX-08	Undisclosed	Undisclosed	Undisclosed	[174]
ADC Info	AT-01	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	AT-00	Undisclosed	Undisclosed	Undisclosed	[176]
ADC Info	AT-04	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	AT-03	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	Antibody drug conjugate containing duocarmycin analogue	Undisclosed	Undisclosed	Undisclosed	[177]
ADC Info	Antibody drug conjugate (Halozyme)	Undisclosed	Undisclosed	Undisclosed	[178]
ADC Info	APB-CS	Undisclosed	Undisclosed	Undisclosed	[179]
ADC Info	Anti-cancer therapeutic (Amgen)	Undisclosed	Undisclosed	Undisclosed	[180]
ADC Info	AK 30 NGF	Undisclosed	Undisclosed	Undisclosed	[181]
ADC Info	ADRX-863	Undisclosed	Undisclosed	Undisclosed	[182]
ADC Info	STING based antibody-drug conjugate (Exelixis)	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[183]
ADC Info	Dual-payload ADC (Mersana Therapeutics)	AF-HPA+DNA monoalkylator I-BiP	Microtubule (MT); Human Deoxyribonucleic acid (hDNA)	Undisclosed	[184]
ADC Info	Alpha-amanitin antibody-drug conjugate (Agensys)	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[185]
ADC Info	Eribulin ADC (Jiangsu hengrui)	Eribulin	Microtubule (MT)	Undisclosed	[186]
ADC Info	Masked ADC (Adagene/ADC Therapeutics)	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[187]
ADC Info	ADC2313	Undisclosed	Undisclosed	Undisclosed	[188]
ADC Info	ADC2154	Undisclosed	Undisclosed	Undisclosed	[189]
ADC Info	ADC2231	Undisclosed	Undisclosed	Undisclosed	[190]
ADC Info	ADC2335	Undisclosed	Undisclosed	Undisclosed	[191]
ADC Info	ADC2317	Undisclosed	Undisclosed	Undisclosed	[192]
ADC Info	BR-2202	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BR-2102	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BR-2003	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BB-1708	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BB-1706	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BB-1712	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	BB-1710	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	MABS-01	Undisclosed	Undisclosed	Undisclosed	[194]
ADC Info	MABS-02	Undisclosed	Undisclosed	Undisclosed	[194]
ADC Info	PBX-002	Undisclosed	Undisclosed	Undisclosed	[195]
ADC Info	SY-1700	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	SY-1274	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	SY-0831	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	SY-1330	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	BRKB-44	Undisclosed	Undisclosed	Undisclosed	[196]
ADC Info	AMB-102	Undisclosed	Undisclosed	Undisclosed	[197]
ADC Info	AU-011	IRDye 700DX	Undisclosed	Undisclosed	[198]
ADC Info	IMB-202	Undisclosed	Undisclosed	Undisclosed	[199]
ADC Info	BIO105	Undisclosed	Undisclosed	Undisclosed	[200]
ADC Info	CO-1003	Undisclosed	Undisclosed	Undisclosed	[201]
ADC Info	CO-1023	Undisclosed	Undisclosed	Undisclosed	[201]
ADC Info	BR107	Undisclosed	Undisclosed	Undisclosed	[202]
ADC Info	BRY811	Undisclosed	Undisclosed	Undisclosed	[203]
ADC Info	OTV:CH2	Undisclosed	Undisclosed	Undisclosed	[204]
ADC Info	OTV:LF3	Undisclosed	Undisclosed	Undisclosed	[204]
ADC Info	IN30728	Undisclosed	Undisclosed	Undisclosed	[205]
ADC Info	IBI130	Undisclosed	Undisclosed	Undisclosed	[5]
ADC Info	FG-B310	Undisclosed	Undisclosed	Undisclosed	[121]
ADC Info	ADC002 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[122]
ADC Info	ADC003 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[122]
ADC Info	TST013	Undisclosed	Undisclosed	Undisclosed	[206]
ADC Info	CS5005	Undisclosed	Undisclosed	Undisclosed	[207]
ADC Info	CS5006	Undisclosed	Undisclosed	Undisclosed	[207]
ADC Info	CHB-111	Undisclosed	Undisclosed	Undisclosed	[208]
ADC Info	RG-7986	Undisclosed	Undisclosed	Undisclosed	[209]
ADC Info	SC-007	Undisclosed	Undisclosed	Undisclosed	[210]
ADC Info	MRG-009	Undisclosed	Undisclosed	Undisclosed	[211]
ADC Info	MRG-008	Undisclosed	Undisclosed	Undisclosed	[212]
ADC Info	MRG-007	Undisclosed	Undisclosed	Undisclosed	[213]
ADC Info	MRG-005	Undisclosed	Undisclosed	Undisclosed	[214]
ADC Info	KSI-201	Undisclosed	Undisclosed	Undisclosed	[215]
ADC Info	BIOO-7	Undisclosed	Undisclosed	Undisclosed	[216]
ADC Info	BIOO-6	Undisclosed	Undisclosed	Undisclosed	[217]
ADC Info	BIOO-5	Undisclosed	Undisclosed	Undisclosed	[218]
ADC Info	Monovalent Azymatic Antibody Drug Conjugate (Zymeworks)	Undisclosed	Undisclosed	Undisclosed	[219]
ADC Info	Antibody-drug conjugate (University of Toronto/ImmunoBiochem)	Undisclosed	Undisclosed	Undisclosed	[220]
ADC Info	Antibody-drug conjugate (University of Toronto/Advanced Proteome Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[221]
ADC Info	Multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene)	Undisclosed	Undisclosed	Undisclosed	[222]
ADC Info	LCB14-2nm	Undisclosed	Undisclosed	Undisclosed	[223]
ADC Info	CYP-Ab	Undisclosed	Undisclosed	Undisclosed	[224]
ADC Info	Antibody drug conjugate (Sanofi)	Undisclosed	Undisclosed	Undisclosed	[225]
ADC Info	Antibody drug conjugate (Compugen)	Undisclosed	Undisclosed	Undisclosed	[226]
ADC Info	Antibody-drug conjugate therapy (Neoantigenics)	Undisclosed	Undisclosed	Undisclosed	[227]
ADC Info	Antibody drug conjugate (Meditope Biosciences)	Undisclosed	Undisclosed	Undisclosed	[228]
ADC Info	LIN-003	Undisclosed	Undisclosed	Undisclosed	[229]
ADC Info	Antibody drug conjugate (Intrexon)	Undisclosed	Undisclosed	Undisclosed	[230]
ADC Info	CRC-02 targeting antibody-drug conjugate	Undisclosed	Undisclosed	Undisclosed	[231]
ADC Info	Antibody-drug conjugate (Daiichi Sankyo)	Undisclosed	Undisclosed	Undisclosed	[232]
ADC Info	Antibody drug conjugate (Asana BioSciences)	Undisclosed	Undisclosed	Undisclosed	[233]
ADC Info	Antibody-drug conjugate (Bristol-Myers Squibb)	Undisclosed	Undisclosed	Undisclosed	[234]
ADC Info	Marine-derived cytotoxic payloads antibody-drug conjugation	Undisclosed	Undisclosed	Undisclosed	[235]
ADC Info	Antibody drug conjugate (Five Prime cancer)	Undisclosed	Undisclosed	Undisclosed	[236]

Ref 1	Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg Oncol. 1993;2(1):31-42. doi: 10.1016/0960-7404(93)90042-w.
Ref 2	Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. Cancer Res. 1997 Feb 15;57(4):678-85.
Ref 3	Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25914-25921. doi: 10.1002/anie.202109835. Epub 2021 Nov 5.
Ref 4	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102.
Ref 5	Innoventbio 2022 Annual Performance Report.
Ref 6	Antibody-drug conjugate CPO204 obtains clinical trial approval in the U.S.
Ref 7	Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor. Journal of Clinical Oncology 2021 39:15_suppl, 1081-1081.
Ref 8	A Study of DB-1202 Monotherapy in Advanced Solid Tumors.
Ref 9	DAC biotechnology company product pipeline
Ref 10	MabGen biotechnology company product pipeline
Ref 11	https://tubulis.com/
Ref 12	An ADC product of CSPC Pharmaceutical Group was approved for clinical use; 2023
Ref 13	Introduction to basic information on ADC drug DS001
Ref 14	First in Human Study of TORL-3-600 in Participants With Advanced Cancer.
Ref 15	Hengrui R&D pipeline.
Ref 16	First in Human Study of TORL-4-500 in Participants With Advanced Cancer.
Ref 17	An overview of hu5B1-TCO.
Ref 18	RemeGen biopharmaceutical company clinical-stage drug candidates and selected IND-enabling stage candidates; 30 Jun 2022.
Ref 19	ADC drug XYD-9668-198 antibody conjugating agent for injection passed the review of the State Drug Administration Drug Review Center and was granted implied permission for clinical trials.
Ref 20	Evopoint biosciences product pipeline
Ref 21	Introduction to basic information on ADC drug DXC1002
Ref 22	Post translational modification therapeutics product pipeline
Ref 23	Introduction to basic information on ADC drug bi-specific antibody drug conjugates(Zymeworks).
Ref 24	Y-Biologics biotechnology company product pipeline
Ref 25	Introduction to basic information on ADC drug BC5084 by Veri.larvol.
Ref 26	Westlake therapeutics product pipeline
Ref 27	ADC review: basic information about VIS705.
Ref 28	Introduction to basic information on ADC drug VLS-201.
Ref 29	Vaccinex and catalent biologics to collaborate on ADC development; 2017
Ref 30	Tot biopharm annual announcement; 2021
Ref 31	Topmunnity therapeutics company product pipeline
Ref 32	Introduction to basic information on ADC drug SI-M-005A.
Ref 33	Introduction to basic information on ADC drug SI-M-002A.
Ref 34	Introduction to basic information on ADC drug SI-B-004A.
Ref 35	ADC review: basic information about BL-B029A1.
Ref 36	ADC review: basic information about BL-M002A2.
Ref 37	Next generation drug conjugates for cancer treatment.
Ref 38	Medilink biotechnology company product pipeline
Ref 39	Introduction to basic information on BsAb-ADC (Medilink Therapeutics).
Ref 40	Antibody drug conjugates SOT106
Ref 41	Introduction to basic information on ADC drug SMD-3117.
Ref 42	Huiyu pharma semi-annual report; 2022
Ref 43	Introduction to basic information on ADC drug BL-M005.
Ref 44	Biokin pharma Prospectus; 2022
Ref 45	Enduring biotechnology company product pipeline
Ref 46	Enduring biotechnology company product pipeline
Ref 47	Introduction to basic information on ADC drug SY-1558
Ref 48	Micurx biopharmaceutical company product pipeline
Ref 49	Introduction to basic information on ADC drug SGN-25.
Ref 50	Salubris biotherapeutics announces $35 million financing to advance development activities and provides pipeline updates; 28 Mar 2023.
Ref 51	Introduction to basic information on ADC drug RAD-501.
Ref 52	PrimeLink bio therapeutics product pipeline
Ref 53	PrecisemAb biotechnology company product pipeline
Ref 54	Introduction to basic information on ADC drug DN-028.
Ref 55	Pheno therapeutics product pipeline
Ref 56	Introduction to basic information on ADC drug antibody-drug conjugate containing OXS-2175(Oxis Biotech/MultiCell ImmunoTherapeutics).
Ref 57	Introduction to basic information on ADC drug OX-004.
Ref 58	Oxford Biotherapeutics product pipeline
Ref 59	Introduction to basic information on next generation antibody-drug conjugates(Oxford BioTherapeutics).
Ref 60	NewBio Therapeutics company product pipeline
Ref 61	NewBio Therapeutics company product pipeline
Ref 62	NewBio Therapeutics company product pipeline
Ref 63	Nectin therapeutics biotechnology company product pipeline
Ref 64	Antibody drug conjugates SOT107
Ref 65	Introduction to basic information on ADC drug NBE-003.
Ref 66	Introduction to basic information on ADC drug NBE-001.
Ref 67	Multitude Therapeutics biopharmaceutical company product pipeline.
Ref 68	Introduction to basic information on ADC drug G-100 (Magenta Therapeutics).
Ref 69	Mablink bioscience company product pipeline
Ref 70	Legochem biosciences biopharmaceutical company product pipeline
Ref 71	ADC review: basic information about LCB14-15NM.
Ref 72	Lanova medicines biotechnology company product pipeline
Ref 73	Introduction to basic information on ADC drug LIN-003.
Ref 74	Kangabio biotechnology company product pipeline
Ref 75	Immunobiochem biotechnology company product pipeline
Ref 76	Iksuda therapeutics product pipeline
Ref 77	Heidelberg pharma product pipeline
Ref 78	Kind Pharmaceuticals LLC company product pipeline.
Ref 79	Gmax biopharm biopharmaceutical company product pipeline
Ref 80	Research programme: glycodesigned biotherapeutics (SeeloMab-GEX)-Glycotope; 28 Mar 2018.
Ref 81	Oligomerization improves endostatin as antiangi-ogenic and anticancer drug (P-1000)
Ref 82	Introduction to basic information on ADC drug GF-2014.
Ref 83	Genequantum biopharmaceutical company product pipeline
Ref 84	ADC review: basic information about EP-400.
Ref 85	Epinogen biotechnology company product pipeline
Ref 86	Dualitybio biotechnology company product pipeline
Ref 87	Defence Therapeutics company product pipeline in Development.
Ref 88	Introduction to basic information on ADC drug CM-09(Curemeta).
Ref 89	Cstone pharma product pipeline
Ref 90	Introduction to basic information on ADC drug CBP-1609.
Ref 91	Introduction to basic information on ADC drug CAT-03-106.
Ref 92	Introduction to basic information on ADC drug BMT-125961.
Ref 93	Brickbio biotechnology company product pipeline
Ref 94	boostimmune biotechnology company product pipeline
Ref 95	Introduction to basic information on ADC drug BSC-4201.
Ref 96	Introduction to basic information on ADC drug BSC-4101
Ref 97	Biocytogen biotechnology company product pipeline
Ref 98	Introduction to basic information on ADC drug JY-023.
Ref 99	AVIPEP Therapeutics product pipeline
Ref 100	Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 101	Introduction to basic information on monoclonal antibody-drug conjugate(Antengene).
Ref 102	AIMEDBIO biotechnology company product pipeline.
Ref 103	ADC review: basic information about ABGN-108.
Ref 104	ADC review: basic information about BL-M005A2.
Ref 105	Xiling yuan pharmaceutical company product pipeline
Ref 106	Cybrexa therapeutics product pipeline
Ref 107	Aphios biotechnology company product pipeline
Ref 108	Heidelberg pharma ATACs fighting cancer; 2020
Ref 109	Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo. Cancer Res (2021) 81 (13_Supplement): 921.
Ref 110	Introduction to basic information on ADC drug Spliceostatin-antibody-drug conjugate
Ref 111	Mersana biopharmaceutical company product pipeline
Ref 112	F-star biotechnology company product pipeline
Ref 113	Introduction to basic information on ADC drug EX108.
Ref 114	Adcentrx therapeutics product pipeline
Ref 115	Symray biopharmaceutical company product pipeline
Ref 116	Introduction to basic information on ADC drug AMB-101
Ref 117	JINFA pharmaceutical company product pipeline
Ref 118	Introduction to basic information on ADC drug 3-NAntC
Ref 119	Bioray R&D pipeline.
Ref 120	An overview of NW-001.
Ref 121	FutureGen R&D pipeline.
Ref 122	Arbelebio R&D pipeline.
Ref 123	Introduction to basic information on ADC drug ZV03-ADC.
Ref 124	Introduction to basic information on ADC drug second ADC (Virtuoso Therapeutics).
Ref 125	Introduction to basic information on ADC drug lead ADC (Virtuoso Therapeutics).
Ref 126	Introduction to basic information on ADC drug additional ADCs (Virtuoso Therapeutics).
Ref 127	Introduction to basic information on ADC drug VLS-301.
Ref 128	Introduction to basic information on ADC drug Vas-202.
Ref 129	Introduction to basic information on ADC drug Vas-201.
Ref 130	ADC review: basic information about TGM-005.
Ref 131	ADC review: basic information about TGM-004.
Ref 132	ADC review: basic information about TGM-003.
Ref 133	ADC review: basic information about TGM-002.
Ref 134	TAE Life Sciences company product pipeline
Ref 135	Introduction to basic information on antibody-drug conjugate 4(Synthon).
Ref 136	Introduction to basic information on antibody-drug conjugate 3(Synthon).
Ref 137	Syntab therapeutics biotechnology company product pipeline
Ref 138	Synaffix is a biotechnology company product pipeline
Ref 139	Sirenas biotechnology company announcement; 2016
Ref 140	Introduction to basic information on ADC drug MRG006.
Ref 141	Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates; 2022
Ref 142	Introduction to basic information on ADC drug APEC-3.
Ref 143	Introduction to basic information on ADC drug APEC-2.
Ref 144	Introduction to basic information on ADC drug DN-027.
Ref 145	Oxford biotherapeutics and boehringer ingelheim agree on 2 year extension to their second multi-year collaboration in cancer immunology; 2023
Ref 146	NewBio Therapeutics company product pipeline
Ref 147	NewBio Therapeutics company product pipeline
Ref 148	Introduction to basic information on ADC drug NW-12-005.
Ref 149	Introduction to basic information on ADC drug MBC-301
Ref 150	Legochem biosciences: Biopharmaceutical company with robust milestone potential; 2019
Ref 151	Introduction to basic information on ADC drug LP-A18.
Ref 152	Introduction to basic information on ADC drug IOG-101.
Ref 153	Introduction to basic information on ADC drug DBAF-301.
Ref 154	Introduction to basic information on ADC drug IN30718.
Ref 155	Introduction to basic information on ADC drug 131I-ImmuRAIT-HCG (Immunomedics).
Ref 156	Introduction to basic information on ADC drug glaucoma therapy(Houston).
Ref 157	Introduction to basic information on ADC drug Gbm12401.
Ref 158	Introduction to basic information on ADC drug GMA-305.
Ref 159	Introduction to basic information on ADC drug GL-231
Ref 160	Futuregen biopharmaceutical company product pipeline
Ref 161	EvolveImmune therapeutics product pipeline
Ref 162	Safety Assessment of Antibody Drug Conjugates.
Ref 163	Introduction to basic information on ADC drug Antiviral Fc-conjugates(Cidara Therapeutics).
Ref 164	Introduction to basic information on ADC drug CRB-2107.
Ref 165	Introduction to basic information on ADC drug monoclonal Antibody-Drug Conjugates(Celltrion Chemical Research Institute/Immunogen/Celltrion).
Ref 166	Introduction to basic information on ADC drug CT-P26.
Ref 167	Blueshield pharma product pipeline
Ref 168	Introduction to basic information on ADC drug BSI-023.
Ref 169	Introduction to basic information on ADC drug BIOO-4.
Ref 170	Introduction to basic information on ADC drug BIOO-3.
Ref 171	Introduction to basic information on ADC drug BIOO-2.
Ref 172	Introduction to basic information on ADC drug BIOO-1.
Ref 173	Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 174	Neoletix biotechnology company product pipeline
Ref 175	Axcynsis therapeutics product pipeline
Ref 176	Introduction to basic information on ADC drug AT-00
Ref 177	Introduction to basic information on ADC drug Antibody drug conjugate containing duocarmycin analogue
Ref 178	Research programme : antibody drug conjugate-Halozyme; 28 Feb 2021.
Ref 179	Introduction to basic information on ADC drug APB-CS
Ref 180	Introduction to basic information on monoclonal anti-cancer therapeutic (Amgen).
Ref 181	Introduction to basic information on ADC drug AK 30 NGF; 27 Nov 2000.
Ref 182	Adcentrx therapeutics product pipeline
Ref 183	Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies; 2022
Ref 184	An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells. Cancer Res (2019) 79 (13_Supplement): 232.
Ref 185	Introduction to basic information on alpha-amanitin antibody-drug conjugates(Agensys).
Ref 186	Introduction to basic information on eribulin ADC (Jiangsu hengrui)
Ref 187	Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 188	Introduction to basic information on ADC drug ADC2313
Ref 189	Introduction to basic information on ADC drug ADC2154
Ref 190	Introduction to basic information on ADC drug ADC2231
Ref 191	Introduction to basic information on ADC drug ADC2335
Ref 192	Introduction to basic information on ADC drug ADC2317
Ref 193	Bliss Biopharmaceutical company product pipeline
Ref 194	Manhattan biotech company product pipeline
Ref 195	Pinotbio biotechnology company product pipeline
Ref 196	Brickbio biotechnology company product pipeline
Ref 197	AmMax biotechnology company product pipeline
Ref 198	Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors. Cancer Immunol Immunother. 2023 Jul;72(7):2405-2422. doi: 10.1007/s00262-023-03425-3. Epub 2023 Mar 30.
Ref 199	ADC review IMB-202
Ref 200	Boostimmune R&D pipeline.
Ref 201	Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition.
Ref 202	An overview of BR107.
Ref 203	An overview of BRY811.
Ref 204	Denali Therapeutics 2021.
Ref 205	Inxmed R&D pipeline.
Ref 206	Transcenta Holding Limited 2022 annual report.
Ref 207	Cstonepharma R&D pipeline.
Ref 208	Introduction to basic information on ADC drug CHB-111.
Ref 209	ADC review: basic information about RG7986.
Ref 210	Prospective grant of an exclusive patent license: anti-CD56 as an antibody-drug conjugate or non-ADC to target glioblastoma either alone or in combination with other potential immuno-oncology drugs; 2020
Ref 211	Introduction to basic information on ADC drug MRG009.
Ref 212	Introduction to basic information on ADC drug MRG008.
Ref 213	Introduction to basic information on ADC drug MRG007.
Ref 214	Introduction to basic information on ADC drug MRG005.
Ref 215	Introduction to basic information on ADC drug LM-317.
Ref 216	Introduction to basic information on ADC drug BIOO-7.
Ref 217	Introduction to basic information on ADC drug BIOO-6.
Ref 218	Introduction to basic information on ADC drug BIOO-5.
Ref 219	Introduction to basic information on ADC drug monovalent azymatic antibody drug conjugate(Zymeworks).
Ref 220	Immunobiochem corporation partners with the centre for the commercialization of antibodies and biologics at the university of toronto to advance new antibody drug conjugates; 2016
Ref 221	Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto; 28 Nov 2020.
Ref 222	Introduction to basic information on ADC drug multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene).
Ref 223	ADC review: basic information about LCB14-2NM.
Ref 224	Introduction to basic information on ADC drug CYP-Ab.
Ref 225	Introduction to basic information on antibody drug conjugates(Sanofi).
Ref 226	Compugen's antibody drug conjugate program results presented; 19 Oct 2015.
Ref 227	University of Virginia spinoff neoantigenics announces collaboration with Pfizer, investment from CIT to develop antibody-based therapeutics for cancer; 2014
Ref 228	Meditope biosciences presentation; 2014
Ref 229	Introduction to basic information on ADC drug LIN-003.
Ref 230	Introduction to basic information on antibody drug conjugates(Intrexon).
Ref 231	Introduction to basic information on ADC drug CRC-02 targeting antibody-drug conjugate(Igenica).
Ref 232	Introduction to basic information on antibody-drug conjugates(Daiichi Sankyo).
Ref 233	Introduction to basic information on ADC drug Antibody drug conjugate (Asana BioSciences)
Ref 234	Bristol-myers squibb and ambrx announce collaboration for novel biologics programs in diabetes and heart failure
Ref 235	Introduction to basic information on antibodies conjugated to marine-derived cytotoxic payloads(Seattle Genetics).
Ref 236	Five prime therapeutics licenses antibodies to seattle genetics for use in novel antibody drug conjugate (ADC) programs; 2020